Number (%) of patients with treatment emergent adverse events or infections (occurring in ⩾5% of patients in either treatment group)
| Adverse event | Placebo (n = 39) | Etanercept (n = 45) | p Value* |
|---|---|---|---|
| *Difference in occurrence, by Fisher’s exact test. | |||
| Injection site reactions | 6 (15) | 15 (33) | 0.028 |
| Haemorrhage, injection site | 4 (10) | 8 (18) | 0.367 |
| Headache | 4 (10) | 6 (13) | 0.745 |
| Nausea | 4 (10) | 3 (7) | 0.699 |
| Asthenia | 1 (3) | 5 (11) | 0.209 |
| Vertigo | 3 (8) | 0 | 0.096 |
| Diarrhoea | 2 (5) | 2 (4) | 1.000 |
| Pruritus | 2 (5) | 2 (4) | 1.000 |
| Pain, abdomen | 2 (5) | 1 (2) | 0.595 |
| Paraesthesia | 2 (5) | 1 (2) | 0.595 |
| Arthralgia | 2 (5) | 0 | 0.213 |
| Haemorrhage, gastrointestinal | 2 (5) | 0 | 0.213 |
| Injury accidental | 2 (5) | 0 | 0.213 |
| Pain, back | 2 (5) | 0 | 0.213 |
| Throat irritation | 2 (5) | 0 | 0.213 |